• 1
    Reed EF, Demetris AJ, Hammond E et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25: 153159.
  • 2
    Hammond ME, Stehlik J, Snow G et al. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: A study of 3,170 biopsies. J Heart Lung Transplant 2005; 24: 20152021.
  • 3
    Bonnaud EN, Lewis NP, Masek MA, Billingham ME. Reliability and usefulness of immunofluorescence in heart transplantation. J Heart Lung Transplant 1995; 14: 163171.
  • 4
    Behr TM, Feucht HE, Richter K et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999; 18: 904912.
  • 5
    Crespo-Leiro MG, Veiga-Barreiro A, Domenech N et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): Incidence, management, and the value of C4d for diagnosis. Am J Transplant 2005; 5: 25602564.
  • 6
    Rodriguez ER, Skojec DV, Tan CD et al. Antibody-mediated rejection in human cardiac allografts: Evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 2005; 5: 27782785.
  • 7
    Cherry R, Nielsen H, Reed E, Reemtsma K, Suciu-Foca N, Marboe CC. Vascular (humoral) rejection in human cardiac allograft biopsies: Relation to circulating anti-HLA antibodies. J Heart Lung Transplant 1992; 11: 2429.
  • 8
    Chantranuwat C, Qiao JH, Kobashigawa J, Hong L, Shintaku P, Fishbein MC. Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: Comparison to frozen tissue immunofluorescence. Appl Immunohistochem Mol Morphol 2004; 12: 166171.
  • 9
    Smith RN, Brousaides N, Grazette L et al. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant 2005; 24: 12021210.
  • 10
    Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 17101720.
  • 11
    Lones MA, Czer LS, Trento A, Harasty D, Miller JM, Fishbein MC. Clinical-pathologic features of humoral rejection in cardiac allografts: A study in 81 consecutive patients. J Heart Lung Transplant 1995; 14: 151162.
  • 12
    Michaels PJ, Espejo ML, Kobashigawa J et al. Humoral rejection in cardiac transplantation: Risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 5869.
  • 13
    Ollert MW, Kadlec JV, David K, Petrella EC, Bredehorst R, Vogel CW. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol 1994; 153: 22132221.
  • 14
    Tan CD, Baldwin WM III, Rodriguez ER. Update on cardiac transplantation pathology. Arch Pathol Lab Med 2007; 131: 11691191.
  • 15
    Olsen SL, Wagoner LE, Hammond EH et al. Vascular rejection in heart transplantation: Clinical correlation, treatment options, and future considerations. J Heart Lung Transplant 1993; 12: S135S142.
  • 16
    Miller LW, Wesp A, Jennison SH et al. Vascular rejection in heart transplant recipients. J Heart Lung Transplant 1993; 12: S147S152.
  • 17
    Koller H, Steurer W, Mark W et al. Clearance of C4d deposition after successful treatment of acute humoral rejection in follow-up biopsies: A report of three cases. Transpl Int 2004; 17: 177181.
  • 18
    Morgan BP, Dankert JR, Esser AF. Recovery of human neutrophils from complement attack: Removal of the membrane attack complex by endocytosis and exocytosis. J Immunol 1987; 138: 246253.
  • 19
    Haun JB, Baldwin WM III, Alevriadou BR. Clearance of complement by human vascular endothelial cells: Effects of hypoxia/reoxygenation and IL-1beta activation. Transpl Int 2005; 18: 475482.
  • 20
    Fredrich R, Toyoda M, Czer LS et al. The clinical significance of antibodies to human vascular endothelial cells after cardiac transplantation. Transplantation 1999; 67: 385391.
  • 21
    Rose ML. De novo production of antibodies after heart or lung transplantation should be regarded as an early warning system. J Heart Lung Transplant 2004; 23: 385395.
  • 22
    Suciu-Foca N, Reed E, Marboe C et al. The role of anti-HLA antibodies in heart transplantation. Transplantation 1991; 51: 716724.
  • 23
    Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753760.
  • 24
    Koch CA, Khalpey ZI, Platt JL. Accommodation: Preventing injury in transplantation and disease. J Immunol 2004; 172: 51435148.
  • 25
    Ding JW, Zhou T, Ma L et al. Expression of complement regulatory proteins in accommodated xenografts induced by anti-alpha-Gal IgG1 in a rat-to-mouse model. Am J Transplant 2008; 8: 3240.
  • 26
    Dalmasso AP, Benson BA, Johnson JS, Lancto C, Abrahamsen MS. Resistance against the membrane attack complex of complement induced in porcine endothelial cells with a Gal alpha(1–3)Gal binding lectin: Up-regulation of CD59 expression. J Immunol 2000; 164: 37643773.
  • 27
    Gonzalez-Stawinski GV, Tan CD, Smedira NG, Starling RC, Rodriguez ER. Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection. J Heart Lung Transplant 2008; 27: 357361.
  • 28
    Keslar K, Rodriguez ER, Tan CD, Starling RC, Heeger PS. Complement gene expression in human cardiac allograft biopsies as a correlate of histologic grade of injury. Transplantation 2008; 86: 13191321.